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Lack ofprognostic significance ofepidermal growth factor receptor and the
oncoprotein p185HER 2 in patients with systemically untreated non-small-
cell lung cancer: an immunohistochemical study on cryosections
P Pfeiffer', PP Clausen2, K Andersen3 and C Rose'
Departments of'Oncology, 2Pathology and 3Thoracic Surgery, Odense University Hospital, Denmark.
Summary The prognostic role of the epidermal growth factor receptor (EGFR) and the related receptor
p185HER-2 in lung cancer is as yet undefined. We investigated the immunohistochemical expression of EGFR
(monoclonal antibody RI; Amersham) and pl85HER-2 (polyclonal antibody A485; Dako) in cryosections. A
total of 186 unselected and systemically untreated patients with non-small-cell lung cancer (NSCLC) diagnosed
and treated at Odense University Hospital, Denmark, were included. Median follow-up period was 66 months.
EGFR and pl85HER-2 was highly expressed in 55% and 26% of cases respectively. Expression of EGFR was
independent of pl85HER-2 expression. The expression of EGFR was higher in squamous cell carcinomas
whereas the level of pl85HER-2 staining was higher in adenocarcinomas. Expression of either or both receptors
was not correlated with age, histological grading, stage and prognosis. We conclude that immunohistochemical
detection of these growth factor receptors failed to demonstrate a prognostic significance in patients operated
on for NSCLC.
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The improvement in survival for most cancer patients has
only been modest and lung cancer is no exception to this rule.
Surgical resection alone offers a chance of cure in early-stage
non-small-cell lung cancer (NSCLC) (Mountain, 1994).
However, some clinical trials indicate possible benefit from
adjuvant (Souquet et al., 1993) or neoadjuvant chemotherapy
(Rosell et al., 1994; Roth et al., 1994). A prerequisite for
further substantiation of these observations is, however, a
proper prognostic classification of these patients. A whole
cascade of tumour-biological characteristics related to
growth, invasion and metastatic potential has been suggested
for their possible prognostic value (Gazdar, 1994; Richardson
and Johnson, 1993). The main criticisms of most prognostic
studies are small sample size, non-homogeneous populations
owing to selection bias and use of optimal cut-off values for
prognostic variables without a prestated hypothesis (Altman
et al., 1994; Simon and Altman, 1994). In addition, various
techniques have been employed without proper methodolo-
gical validation. Not surprisingly, conflicting results have
been obtained and it is still not possible to conclude which
factors give valid prognostic information.
The protein product of the oncogene HER-1, the
epidermal growth factor receptor (EGFR), is a 170 kilo-
dalton (kDa) transmembrane protein, exhibiting an extra-
cellular ligand-binding area, a transmembrane domain and an
intracellular region with tyrosine kinase activity. The receptor
is able to activate cytoplasmic signal proteins that trigger
DNA synthesis associated with proliferation and differentia-
tion (Prigent and Lemoine, 1992).
It has recently been shown that the HER-2 (or c-erbB-2)
proto-oncogene encodes a 185 kDa glycoprotein (pl85HER-2),
which has molecular homology with EGFR. Like EGFR, the
p185HER-2 is a transmembrane receptor with tyrosine kinase
activity (Prigent and Lemoine, 1992).
The type 1 (EGFR-related) family of growth factor
receptors is important in the regulation of normal cells and
in the carcinogenic process (Prigent and Lemoine, 1992), but
whether expression of these receptors reflects prognosis
remains to be established.
To determine whether immunohistochemical detection of
EGFR and/or pl85HER-2 in frozen tissue is of prognostic
importance in patients with NSCLC, we conducted the
present hypothesis-generating study in a homogeneously
treated and unselected cohort of 186 patients. With the
exception of two patients, cytotoxic therapy had not been
given during the course of the disease.
Materials and methods
Patients and tumour samples
A total of 186 patients with NSCLC were followed for a
median of 66 (40-119) months. The 131 men and 55 women
had a median age of 61 (42-79) years at the time of
diagnosis. Characteristics of patients were collected from
their records (Table I).
All the patients were treated surgically at the Department
of Thoracic Surgery at Odense University Hospital, Den-
mark, from 1984 to 1991. Pulmonary resection was
accompanied by intraoperative evaluation of tumour exten-
sion with biopsy of suspicious areas and lymph nodes;
complete mediastinal lymph node dissection or systematic
lymph node sampling was not performed. The stage of the
primary tumour (Table I) was determined retrospectively,
including a review of the surgical and pathological reports,
according to the new International Staging System for lung
cancer (Mountain, 1994).
The surgical procedure was considered radical in 152
patients (microscopic radical, 104; macroscopic radical, 48),
whereas macroscopic tumour tissue was left in 34 patients.
Post-operative adjuvant therapy was not part of the
treatment strategy. At the discretion of the treating
physician, two patients out of these 186 patients with
NSCLC received cytotoxic therapy during the course of
their disease. No patient received post-operative adjuvant
radiotherapy.
Tissue preparation
Lung tissue was received unfixed in the pathology laboratory
immediately after surgical removal. One piece of tumour
measuring approximately 1 cm3 was cut out and divided. One
part was placed in a cryoconservation tube, snap frozen at
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Table I Characteristics of 186 patients with NSCLC
Parameter n
Total 186
Follow-up (months)
Median
Range
Age (years)
Median
Range
Male
Female
66
40-119
61
42-79
131
55
Histological classification
Squamous cell carcinoma
Adenocarcinoma
Large cell carcinoma
Histological grading
Highly differentiated
Moderately differentiated
Lowly differentiated
Undifferentiated
Stage
I
II
IIIb
IV
Adjuvant therapy
Radiotherapy
Cytotoxic therapy
Surgical procedure
Pneumonectomy
Lobectomy
Segment resection
Exploratory thoracotomy
Radical surgery
Microscopic
Macroscopic
None
102
59
25
15
46
100
25
86
48
41
3
8
0
0
48
115
21
2
104
48
34
-80°C and stored until further examination. The other part
was formalin fixed and embedded in paraffin.
Histological classification
Haematoxylin-eosin (H&E)-stained sections from formalin-
fixed paraffin-embedded tumour specimens were reviewed by
one experienced pathologist (PPC). The morphological
examination, classification and grading of tumours were
performed according to WHO (1981).
Immunohistochemical analysis
Before we started immunohistochemical staining of the entire
material we performed a series of experiments to select the
best antibodies, optimal concentrations and incubation time
of reagents. We examined multitissue blocks containing
unfixed normal tissue and tumours with a known (low and
high) expression of EGFR and pl85HER2. Several antibodies
produced convincing results but the best signal-noise ratio
was obtained with RI (Amersham, UK) and A485 (Dako,
Denmark) respectively.
EGFR and p185HER-2 immunostaining was performed on
cryostat sections, approximately 5 ,um thick, using the
peroxidase-labelled streptavidin-biotin (LSAB) technique.
Frozen sections were air dried and fixed in acetone for
10 min (EGFR), or in 4% neutral buffered formaldehyde for
2 min (pl85HER-2). Tissue sections were then washed twice
with Tris-buffered saline (TBS) for 2 min each and incubated
with blocking serum [bovine serum albumin (BSA) 2%
(Sigma A-7906) in TBS, pH 7.4] for 10 min. Owing to very
low background staining, cryostat sections did not require
blocking of endogenous peroxidase. All the incubations were
performed at room temperature in wet chambers. The
blocking serum was drained off and sections were incubated
with the primary antibody for 30 min; the optimal dilution
had been determined previously (EGFR, 1:100 in 1% BSA/
TBS with 15 mM sodium azide, and p185HER2, 1:300 in 1%
BSA/TBS with 15 mM sodium azide). For detection of
EGFR, we used the murine monoclonal antibody RI. RI is
an IgG2b antibody directed against the extracellular portion
of EGFR (Waterfield et al., 1982). p185HER-2 was detected by
the rabbit polyclonal antibody A485. This antibody was
developed against a peptide sequence from the intracytoplas-
mic part of the human p185HER2.
Sections were washed with TBS and incubated for 30 min
with the biotinylated secondary antibodies (anti-mouse E432
and anti-rabbit E433) (also previously titrated for optimal
dilutions), followed by streptavidin-horseradish peroxidase
(P397) (1:300 in TBS). After washing with TBS the
peroxidase activity was visualised by incubation for 20 min
in 0.04% 3-amino-9-ethylcarbazole solution containing
0.015% hydrogen peroxide, which gives a red-brown
reaction product. After treatment, the sections were washed
with distilled water, counterstained with haematoxylin and
mounted with Aquamount. Human placenta and normal
tonsil tissue were used as positive controls and included in
each staining process. Negative control sections of the
tumour tissue were immunostained under the same condi-
tions, but omitting the primary antibody; reactions were
negative in all cases.
Immunohistochemical assessment
After scanning and evaluation of the entire section under low
power, a representative area was evaluated with high-power
fields ( x 10 eyepiece, x 40 objective). Scoring of the
immunohistochemical results was performed by one author
(PP), who was blinded with regard to the clinical data.
The immunohistochemical staining was scored negative if
membrane staining was absent. Weak but recognisable
staining was classified as grade 1, moderate as grade 2 and
strong as grade 3. When there were different intensities within
the specimen, the highest grade was recorded. Furthermore,
the percentage of positively reacting tumour cells was
estimated using a semiquantitative scale ranging from 0%
to 100%, with 10 per cent intervals. For further analyses,
staining was graded as negative, moderate (<80%) or high
(>80%). The study was approved by the local ethics
committee.
Statistical evaluation
Non-parametric statistics were applied. To compare the
results of two or more subgroups, the Mann-Whitney
(M-W) or Kruskal-Wallis (K-W) tests were used.
Correlations between subgroups were assessed by Spear-
man's rank correlation coefficient (rJ) test. Survival curves
were generated according to the Kaplan-Meier method and
compared by the log-rank test. BMDP statistical software
(BMDP/PC Release 7.01, 1993) was used.
Results
The 186 tumours were distributed as follows:
cell carcinoma, 59 adenocarcinoma and
undifferentiated carcinoma (Table I).
102 squamous
25 large-cell
EGFR andp185HER2
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Table II Relationship between EGFR staining and histological
classification in 186 patients with NSCLC
EGFR staining
No. of None Low High
patients N (%) N (%) N (%)
SQ 102 6 (6) 24 (23) 72 (71)
AD 59 7 (12) 30 (51) 22 (37)
LA 25 1 (4) 15 (60) 9 (36)
Total 186 14 (8) 69 (37) 103 (55)
SQ, squamous cell carcinoma; AD, adenocarcinoma; LA, large-cell
carcinoma. SQ>AD: P<0.001. SQ>LA: P = 0.003.
0 1 2 3 4 5 6 7
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Table III Relationship between p185HER-2 staining and histological
classification in 186 patients with NSCLC
p185HER-2 staining
No. of None Low High
patients N (%) N (%) N (%)
SQ 102 22 (21) 66 (65) 14 (14)
AD 59 4 (7) 25 (42) 30 (51)
LA 25 3 (12) 17 (68) 5 (20)
Total 186 29 (16) 108 (58) 49 (26)
SQ, squamous cell carcinoma; AD, adenocarcinoma; LA, large-cell
carcinoma. AD>SQ: P<0.001. LA>SQ: P < 0.001.
Figure 1 The survival of 186 patients with NSCLC categorised
according to EGFR content (P= 0.9). - - - -, None (n = 14);
, low (n=69); - - -, high (n= 103).
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was observed in the immunostaining of EGFR or p185HER-2
between central and peripheral tumour cells, the peripheral
cells being more often positive. The heterogeneity of
immunohistochemical staining was not correlated with the
tumour morphology as assessed by routine H&E staining or
any other parameter. There was a highly significant
correlation between staining intensity and the percentage of
positive cells for EGFR as well as pl85HER-2 (Spearman;
rs=0.83, P<0.00001). This indicates that both methods may
be used in the immunohistochemical estimation of EGFR
and p185HER-2 content; for the subsequent analyses we have
chosen to use percentage of positive tumour cells. There was
no association between EGFR and p185HER-2 status (Spear-
man; rr =0.004).
EGFR In sections containing bronchial epithelium, we
found membrane staining in the basal cells. The majority of
tumours stained positively for EGFR; the extent of EGFR
expression is shown in Table II. A total of 103 tumours
(55%) were strongly positive (staining of >80% of tumour
cells), whereas only 14 (8%) were negative.
There was a definite relationship between EGFR status
and histology (Table II). Higher expression of EGFR was
found in squamous cell carcinomas of the lung than in large
cell carcinomas and adenocarcinomas (K-W; P=0.001).
EGFR content did not show any significant correlation with
age, tumour size, lymph node involvement, stage or
histological grading.
We found no correlation between EGFR staining and
survival in patients with squamous cell carcinoma (relative
risk 1.14; 95% I 0.79-1.66), adenocarcinoma of the lung,
stage I and/or II, or in the entire group of patients with
NSCLC (Figure 1). This was confirmed, whether we applied
the cut-off points used in Table II (three groups), used
median values (two groups), used quartiles (four groups) or
related survival to intensity of staining.
pJ85HER2 In the normal bronchial epithelium, membrane
staining was most intense at the luminal border. In all, 49
tumours (26%) were strongly positive (staining of 80% of
tumour cells), whereas 29 (16%) were negative. pl85HER-2
0
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Figure 2 The survival of 186 patients with NSCLC categorised
according to pl85HER-2 content (P= 0.9). - - - -, None (n =29);
, low (n= 108); - - -, high (n=49).
status was also related to histology (Table III), but in
contrast to EGFR, the level of p185HER-2 staining was lower
in squamous cell carcinomas than in adenocarcinomas and
large cell carcinomas (K-W; P<0.001). p185HER-2 content
was not correlated with age, tumour size, lymph node
involvement, stage or histological grading.
We found no correlation between p185HER-2 staining and
survival in patients with squamous cell carcinoma, adeno-
carcinoma of the lung (relative risk 0.89; 95% CI 0.56-1.41),
stage I and/or II, nor in the entire group of patients with
NSCLC (Figure 2). This was confirmed, whether we applied
the cut-offpoints for p185HER-2 from Table III (three groups),
used median values (two groups), used quartiles (four groups)
or related survival to intensity of staining.
In vitro studies (Kokai et al., 1989) suggested that
simultaneous overexpression of both EGFR and p185HER-2
acts synergistically. Consequently, we investigated whether
patients with EGFR-positive and p185HER-2_positive tumours
might have a poorer prognosis than patients with over-
expression of either of the receptors or no overexpression at
all. To analyse groups of comparable size we used the median
value as cut-off point for both receptors. As for the
individual receptor, overexpression of both receptors was of
no prognostic significance (P=0.3; Figure 3).
Discussion
A detailed knowledge of prognostic and predictive factors
can be essential for predicting patients' outcome and for
proper selection of treatment, but also for optimal trial
design and for comparison of results. New prognostic factors
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may help to identify patients with poor prognoses, who might
benefit from neoadjuvant (Roth et al., 1994) or post-
operative therapy (Holmes, 1993), and patients with good
prognoses, who can be spared additional therapy. As new
biological markers are constantly being uncovered and
investigated, clinicians are faced with the problem: are these
I-0
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Figure 3 The survival of 186 patients with NSCLC categorised
according to EGFR and pl85HER-2 content (P=0.38). - - - -, high
EGFR and high p185HER-2 (n = 50); , high EGFR or
high p185HER-2 (n = 103); -- -, low EGFR and low pl85HER-2
(n=33).
markers truly independent prognostic factors? Numerous
studies investigating different factors, different cut-off points,
different subsets of patients, and different end points are
performed, often even without a prespecified hypotheses
(Simon and Altman, 1994)
Simon and Altman (1994) have proposed a number of
meaningful guidelines that should be fulfilled before definite
statements are made concerning the prognostic significance
of, for example, the EGF receptor family. In this regard,
breast cancers are probably the best studied group of
malignant tumours, with several large well-conducted studies
which meet most of these guidelines; the majority of large
well-conducted studies of breast cancer have found that
overexpression of the EGF receptor family is associated with
poor prognosis in patients with node-positive breast cancer
although results on node-negative patients remain contra-
dictory. This difference may be caused by a treatment effect,
i.e. EGFR or pl85HER-2 are predictive but not prognostic
factors (Knoop et al., 1994; Ravdin and Chamness, 1995). By
contrast, prognostic studies of the EGF receptor family in
NSCLC that include an adequate number ofpatients are very
few.
EGFR and pl85HER-2 are members of the type 1 (EGFR-
related) family of growth factor receptors (Prigent and
Lemoine, 1992). These receptors are important in the
regulation of normal cell growth, they are connected to the
carcinogenic process and they are potential prognostic factors
in a variety of human malignant tumours (Gullick, 1991;
Prigent and Lemoine, 1992).
Table IV Immunohistochemical detection of EGFR and survival in patients with NSCLC
No. of Histological subtype
Reference patients SQ AD LA Unknown Prognosis Comments
Dazzi et al. (1989) 152 97 31 7 17 NS Patients with 'positive tumours'
% positive 55 45 43 29 tended to have improved survival
Tateishi et al. (1990) 131 131 NS
% positive 42
Volm et al. (1992) 81 81 S Examined 11 potential 'prognostic
% positive 79 factors'
Volm et al. (1993) 121 121 S Stage, EGFR, fos and jun were
% positive 83 prognostic factors
Vohm and Mattern (1993) 88 88 S Evaluated 9 potential 'prognostic
% positive 77 factors'
Rusch et al. (1993) 57 19 31 3 4 NS IH was correlated to mRNA, which
% positive ? had no impact on survival
IH, immunohistochemistry; S, significant; NS, not significant.
Table V Immunohistochemical detection ofp185HER-2 and survival in patients with NSCLC
No. of Histological subtype
Reference patients SQ AD LA Unknown Prognosis Comments
Kern et al. (1990) 55 16 29 10 S for AD Significant by multivariate analysis
% positive 31 34 0
Tateishi et al. (1991) 203 84 119 S for AD
% positive 2 28
Volm et al. (1992) 81 81 NS Examined 11 potential 'prognostic
% positive 36 factors'
Voln et al. (1993) 121 121 NS Examined five potential 'prognostic
% positive 46 factors'
Volm and Mattern (1993) 88 88 NS Examined nine potential 'prognostic
% positive 35 factors'
Kern et al. (1994) 46 46 S Significant by multivariate analysis
% positive 34
Bongiorno et al. (1994) 29 29 NS
% positive 96
IH, immunohistochemistry; S, significant; NS, not significant
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We designed this study to test the hypothesis that EGFR and
p185 ER-2 are of prognostic value in patients operated on for
NSCLC, and we attempted to meet as many of the above-
mentioned guidelines as possible. Furthermore, patients were
not treated with adjuvant cytotoxic therapy even, with the
exception of 2 patients, when recurrent disease was
diagnosed. Thus, we had the possibility of conducting a
plain prognostic study.
In agreement with most other studies, we found expression
of EGFR in all subtypes of NSCLC. but most frequently in
squamous cell carcinomas (Veale et al., 1987; Hendler and
Ozanne. 1984: Sobol et al.. 1987: Kaseda et al., 1989; Berger
et al.. 1987) and no correlation between EGFR and the size
of the primarv tumour, lymph node status or stage (Kaseda
et al.. 1989: Dittadi et al., 1991; Veale et al.. 1989; Di Carlo
et al., 1993; Bolufer et al.. 1993; Rusch et al.. 1993: Dazzi et
al., 1989; Volm and Mattern. 1993).
However, when expression of EGFR or p185HER-2 has been
correlated with outcome, conflicting results are presented. In
some studies. overexpression of EGFR has been an indicator
of bad prognosis (Volm et al., 1992. 1993; Hendler and
Ozanne, 1984: Veale et al.. 1987): in some studies expression
of EGFR had no impact on outcome (Gorgoulis et al., 1992:
Scagliotti et al.. 1993; Rusch et al., 1993). whereas still others
indicated that patients with EGFR-positive tumours may
survive longer than patients without EGFR expression (Dazzi
et al.. 1989: Veale et al.. 1993).
The first immnunohistochemical studies to investigate the
content of EGFR in patients with NSCLC were based on
cryosections (Cerny et al.. 1986; Berger et al.. 1987: Veale et
al., 1987: Sobol et al.. 1987). However, almost all subsequent
studies used paraffin-embedded tissues. Table IV summarises
published immunohistochemical studies that correlate EGFR
with outcome in NSCLC. Three studies (Dazzi et al.. 1989;
Tateishi et al.. 1990; Rusch et al., 1993) failed to find a
correlation between EGFR expression and prognosis.
whereas three other studies, which included patients with
squamous cell carcinoma. showed that a high EGFR content
was correlated with poor prognosis. However, these three
studies. which were all published by Volm et al. (Volm et al..
1992. 1993: Volm and Mattern, 1993), do not state how
patients were selected, and these different studies might at
least partly include the same patients.
The oncogene HER-2 and its gene product pl85HER-2 have
also been studied in NSCLC. In accordance with most studies.
we found that pl85HER, staining was more prominent in
adenocarcinomas than in squamous cell carcinomas and large
cell carcinoma (Kern et al., 1990; Tateishi et al., 1991; Shi etal..
1992). In agreement with most studies, we also found no
relationship between pI85HER-2 and the extension ofthe disease
(Volm et al.. 1992. 1993: Shi et al., 1992; Bongiorno et al..
1994). Most authors agree that p185 IR-' staining is not
correlated with prognosis in patients with squamous cell
carcinoma (Kern et al.. 1990: Volm et al.. 1992. 1993: Tateishi
et al.. 1991). However, a higher content of pl85HER- is
correlated with a diagnosis of adenocarcinoma of the lung.
and p185HER-' may be a prognostic factor in these adenocarci-
nomas (Kern et al.. 1990. 1994: Tateishi et al.. 1991).
Table V summan'ses published immunohistochemical
studies that correlate pl85"R-' with survival in NSCLC.
Kern et al. (1990) examined the expression of pl85HER-2 in 55
patients with NSCLC and operated on between 1982 and
1985. They found that pl85HER-2 expression was associated
with shortened survival in a subgroup of 29 patients with
adenocarcinoma (Kern et al., 1990). In a later study, Kern et
al. (1994) evaluated the prognostic significance of pl85HER-2
expression and ras gene mutations in 46 patients with
pulmonary adenocarcinoma. By univariate and multivariate
analysis they showed that p185HER-' expression was associated
with shortened survival. whereas K-ras mutation approached
significance as a poor prognostic indicator. The impact of
both p185IR-2 expression and a K-ras mutation on survival
was additive and highly significant. However. these 46
patients with adenocarcinomas were operated on during the
same period as the 29 patients previously mentioned (Kern et
al.. 1990) and this indicates some selection bias. Tateishi et al.
(1991) examined p185HER- in 203 patients with NSCLC and
found 5-year survival rates of p185HER positive and
-negative patients of 30% and 52% respectively: they
concluded that the expression of p185HER-2 may serve as a
prognostic indicator in adenocarcinoma of the lung.
Bongiorno et al. (1994) used cryosections to evaluate the
content ofp185HER-2 in 29 patients with adenocarcinomas but
found no correlation with survival. Except for the study by
Bongiorno et al. (1994) and ours, all other studies in Table V
were based on paraffin-embedded tissue.
It is becoming apparent in breast cancer at least (Ravdin
and Chamness. 1995) that overexpression of these receptors is
related to response to therapy (i.e. it is a predictive factor),
and this may explain. at least to some extent, the conflicting
results summarised above.
EGFR and p185HER- are expressed in NSCLC at a higher
level than that of normal bronchial or premalignant tissue
(Di Carlo et al.. 1993). but without correlation with extension
ofdisease once an invasive tumour has developed. These facts
suggest an important step during preinvasive carcinogenesis.
It might provide the potential tumour cell with the ability to
proliferate when the supply of growth factors is restricted
and or escape terminal differentiation. In addition, if these
growth factor receptors and their ligands are important in
tumorigenesis. the data suggest that adenocarcinomas,
squamous cell carcinomas and large cell carcinoma probably
have some carcinogenetic mechanisms in common, regardless
of progenitor cell or anatomical location (Weiner et al..
1990).
In conclusion, the present study failed to demonstrate that
overexpression of EGFR and pl85HER- is prognostic in
systemically untreated patients with NSCLC. Instead EGFR
and pl85HER-2 may be associated with the development of the
primary malignant tumour, but without impact on further
tumour progression, invasion or development of metastasis.
Most studies of EGFR and pl85HER' have used different
monoclonal or polyclonal antibody directed toward different
epitopes of the receptor and before results are incorporated in
the clinical situation, standardisation of the immunohisto-
chemical analyses is therefore indispensable.
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